Related Experiment Video

Updated: Jun 8, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Perspectives: Other ErbB2-Targeted Therapies

Ulrike Nitz1

  • 1Brustzentrum Niederrhein, Evangelisches Bethesda-Krankenhaus, Mönchengladbach, Germany.

Breast Care (Basel, Switzerland)
|September 18, 2010
PubMed

Insights

New targeted therapies are emerging for HER2-positive breast cancer, offering hope beyond existing treatments. These novel agents, including antibodies and kinase inhibitors, show promise for chemotherapy-free options in advanced disease.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Individualized targeted therapies have improved outcomes for breast cancer patients.
  • Resistance to current treatments like trastuzumab and lapatinib remains a challenge.
  • Overexpression of ErbB2 (HER2) is a key target in specific breast cancer subtypes.

Purpose of the Study:

  • To review novel targeted agents for breast cancer with HER2 overexpression.
  • To explore new therapeutic strategies for patients progressing on existing HER2-targeted drugs.
  • To assess the potential of new agents as chemotherapy-free options.

Main Methods:

  • Review of clinical studies on novel targeted agents.
  • Analysis of drug mechanisms, including monoclonal antibodies and tyrosine kinase inhibitors.
  • Evaluation of synergistic effects reported in recent publications.

Main Results:

  • Several novel targeted agents targeting HER2 are in clinical development.
  • These agents include monoclonal antibodies and multifunctional tyrosine kinase inhibitors.
  • Emerging data suggest synergistic effects among new therapeutic substances.

Conclusions:

  • New targeted therapies are being developed for HER2-positive breast cancer resistant to current treatments.
  • These agents represent potential advancements beyond trastuzumab and lapatinib.
  • Future chemotherapy-free treatment options for metastatic breast cancer are a possibility.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...